Abstract: Prostate cancer (PCa) is one of the most commonly diagnosed malignancy in men，and the incidence of PCa has been increasing in China over the past decade. There are several well-established risk factors for PCa，including age and family history of PCa. There is no specific symptom for PCa at early stage，thus it is of great significance to carry out screening and early detection for PCa. Prostate-specific antigen (PSA) testing is the main approach of screening for PCa，multiparametric MRI plays an important role in PCa diagnosis and staging，and TRUS-guided prostate biopsy is the standard of care. The management of PCa is based on the staging and risk stratification，and treatment strategy should be standardized and precise. Radical prostatectomy or external-beam radiation therapy is the gold standard for localized PCa. For metastatic PCa，treatment approaches with demonstrated survival benefit include androgen deprivation therapy combined with novel hormonal therapy，chemotherapy，targeted therapy，and radionuclide therapy.

Key words: prostate cancer, tumor screening, liquid biopsy, precision treatment